Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Intravenous Immunoglobulin in Neurological Disease: A specialist Review
JNNP 72:440-448, Wiles,C.M.,et al, 2002
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997
Recommendations for Off-Label Use of Intravenously Administered Immunoglobulin Preparations
JAMA 273:1865-1870, Ratko,T.A.,et al, 1995
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994
A Plasma Exchange Versus Immune Globulin Infusion Trial in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Ann Neurol 36:838-845, Dyck,P.J.,et al, 1994
Does My District Need a Mobile Stroke Unit?
NEJM 385:971-981,1043, Lees, K.R., 2021
Telemedicine in Prehospital Stroke Evaluation and Thrombolysis
JAMA Neurol 73:162-168, Itrat, A.,et al, 2016
Implementing a Mobile Stroke Unit Program in the United States
JAMA Neurol 72:229-234, Rajan, S.,et al, 2015
Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke
Stroke 46:2591-2598, Ganesalingam, J.,et al, 2015
The Cost-Effectiveness of Telestroke in the Treatment of Acute Ischemic Stroke
Neurol 77:1590-1598, Nelson, R.E.,et al, 2011
Cost-Effectiveness of Multimodal CT for Evaluation Acute Stroke
Neurol 75:1678-1685, Young,K.C.,et al, 2010
Cost-Effectiveness of Patient Selection Using Penumbral-Based MRI for Intravenous Thrombolysis
Stroke 40:1710-1720, Earnshaw,S.R.,et al, 2009
Telemedicine Versus Telephone for Remote Emergency Stroke Consultations: A Critically Appraised Topic
The Neurologist 15:163-166, Capampngan,D.J.,et al, 2009
Is it Time for Neurohospitalists?
Neurol 70:1282-1288, Freeman,W.D.,et al, 2008
Cost-Effectiveness of Intravenous Thrombolysis With Alteplase Within a 3-Hour Window After Acute Ischemic Stroke
Stroke 38:85-89, Ehlers,L.,et al, 2007
Estimated Cost Savings of Increased Use of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Canada
Storke 38:1952-1955,1732, Yip,T.R. &Demaerschalk,B.M., 2007
Long-Term Outcome After Thrombolysis in Telemedical Stroke Care
Neurol 69:898-903,819, Schwab,S.,et al, 2007
Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States
Stroke 36:2500-2503, Demaerschalk,B.M. &Yip,T.R., 2005
Cost-Effectiveness of Diagnostic Strategies Prior to Carotid Endarterectomy
Ann Neurol 58:506-515, U-King-Im,J.M.,et al, 2005
Is Hospitalization After TIA Cost-Effective on the Basis of Treatment With tPA?
Neurol 65:1799-1801, Nguyen-Huynh,M.N. &Johnson,S.C., 2005
Comparison of Diffusion-Weighted MRI and CT in Acute Stroke
Neurol 54:1557-1561,1548,1549,1552, Lansberg,M.G.,et al, 2000
Treatment of Acute Ischemic Stroke
NEJM 343:710-722, Brott, T. & Bogousslavsky, J., 2000
Combined Intravenous and Intra-Arterial r-TPA Versus Intra-Arterial Therapy of Acute Ischemic Stroke, Emergency Management of Stroke (EMS) Bridging Trial
Stroke 30:2598-2605, Lewandowski,C.A.,et al, 1999
Early Intravenous Thrombolysis for Acute Ischemic Stroke in a Community-Based Approach
Stroke 29:1544-1549, Grond,M.,et al, 1998
Cost-Effectiveness of Tissue Plasminogen Activator for Acute Ischemic Stroke
Neurol 50:883-890, Fagan,S.C.,et al, 1998
When is Thrombolysis Justified in Patients with Acute Stroke? A Bioethical Perspective
Stroke 28:214-218, Furlan,A.J.&Kanoti,G., 1997
Cost-effectiveness of Emergency Intraarterial Intracerebral Thrombolysis:A Pilot Study
AJNR 16:1987-1993, 19941995., Lanzieri,C.F.,et al, 1995
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients with Early Alzheimer Disease
Neurol 98:e968-e977, Whittington, M.D.,et al, 2022
Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared with Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
Stroke 49:1464-1470, Reddy, V.Y.,et al, 2018
Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke
Stroke 48:379-387, Shireman, T.I.,et al, 2017
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Cost-Effectiveness of Endovascular Thrombectomy in Patients with Acute Ischemic Stroke
Neurol 86:1053-1059, Aronsson, M.,et al, 2016
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016
Hypoglossal-Nerve Stimulation for Obstructive Sleep Apnea
NEJM 370:170-171, Malhotra, A., 2014
When is Carotid Angioplasty and Stenting the Cost-Effective Alternative for Revascularization of Symptomatic Carotid Stenosis? A Canadian Health System Perspective
AJNR 35:327-332, Almekhlafi, M.A.,et al, 2014
Triptans for Symptomatic Treatment of Migraine Headache
BMJ 348:g2285, Pringsheim, T. & Becker, W.J., 2014
Effect of Telestroke on Emergent Stroke Care and Stroke Outcomes
Stroke 45:1876-1880, Bladin, C.F. & Cadilhac, D.A., 2014
Why Calls for More Routine Carotid Stenting are Currently Inappropriate
Stroke 44:1186-1190, Abbott, A.L.,et al, 2013
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013
Cost-Effectiveness of Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Stroke 43:881-883, Kamel,H.,et al, 2012
Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation
Stroke 42:112-118, Mercaldi,C.J.,et al, 2011
Metastatic spinal cord compression
BMJ 342:d2402, Quraishi, N. & Esler, C., 2011
Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation
Stroke 42:1717-1721, Jowett, S.,et al, 2011
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011